أوروبا · وكالات وأخبار لحظية · ANP

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

نشره ANP · هولندا منذ 10 س

SD-101 (Zorblesia™) is the First Topical Therapy Being Developed to Treat Wounds and Lesions Across the Entire Skin Surface in Patients with Three Major Subtype ...

اقرأ المقال كاملًا على ANP سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (persportaal.anp.nl)

يستحق القراءة أيضًا

TASS

Paradigm Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Trial for SD-101 (Zorblesia™) in Epidermolysis Bullosa

مشاركة

يستحق القراءة أيضًا

European gas futures top $1,050, first time since December 2022

QatarEnergy signs deal to buy 4 million tons of US LNG annually through 2054

Hermes revenue growth slows as Chinese consumers cut spending on accessories

Millions of hacking attempts as companies, governments rush to patch PHP flaws

France's 24-year high borrowing costs could be 'warm up for Germany'

LSEG to buy Octus in $3.5 billion deal to shield from AI disruption